Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2013-05-16 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 1 page 51.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001 Section 671B, titled 'Notice of Ceasing to be a Substantial Holder.' It details changes in relevant interests and associates related to substantial shareholding in Pharmaxis Ltd. This type of filing is a notification about changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is short and focused solely on shareholding changes, not on financial results or management information.
2013-05-16 English
FDA Meeting, Business Review Announcement End of May 2 pages 125.4KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 14 May 2013 from Pharmaxis Ltd announcing a meeting with the FDA to discuss clinical trial parameters for Bronchitol, a drug for cystic fibrosis. It discusses regulatory strategy, clinical trial design, and business review plans. There are no financial statements, earnings data, or detailed financial analysis. The document is an announcement of a regulatory meeting and business update rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory/business update announcement, best classified under Regulatory Filings (RNS).
2013-05-13 English
Becoming a substantial holder 4 pages 61.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 - Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of National Nominees Ltd as Custodian for Australian Ethical Smaller Companies Trust in Pharmaxis Limited, including voting power, relevant interests, and acquisition details. This type of filing is a notification of a major shareholding change, not a financial report, management announcement, or other corporate filing. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2013-05-05 English
Change of Director's Interest Notice 2 pages 74.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares and options held before and after the change, the nature of the transaction (on-market trade), and confirms no trading during a closed period without clearance. This is a clear report of personal share transactions by a company director, which matches the definition of 'Director's Dealing'. The document length is 3501 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is 'DIRS'.
2013-05-02 English
Ceasing to be a substantial holder 2 pages 21.7KB
Major Shareholding Notification Classification · 95% confidence The document is a 'Substantial Shareholder Notice' referencing Form 605 under section 671B(3) of the Corporations Act 2001 (Cth). It details a notice of ceasing to be a substantial holder, including dates and shareholding changes. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (MRQ). The document length is 4126 characters, which is consistent with a detailed notification rather than a brief announcement or a full report. There is no indication of financial statements or management discussion, so it is not an Annual Report or Interim Report. It is not a regulatory announcement or certification, so RNS is not appropriate. Therefore, the correct classification is MRQ with high confidence.
2013-04-28 English
PHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305) 3 pages 113.8KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 24 April 2013 from Pharmaxis Ltd announcing the results of a Phase 3 clinical trial (B305) for Bronchitol in bronchiectasis. It details the trial design, primary and secondary endpoints, and safety outcomes. The content is focused on clinical trial results and company commentary rather than financial data or regulatory filings. It is not an annual report, earnings release, or management discussion. It is also not a regulatory filing or certification. The document is a press release announcing clinical trial results, which fits best under a general regulatory announcement or miscellaneous category since it does not fit the other specific categories like earnings, capital update, or governance. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (9552 characters) and detailed content confirm it is not a brief announcement or report publication notice.
2013-04-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.